One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet… read more.
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds. For patients enrolled in Medicare Part… read more.
Seagen Inc. and Genmab A/S announced that the Phase III innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line… read more.
For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take… read more.
Pfizer Inc. and Astellas Pharma Inc. announced that the FDA has accepted and granted Priority Review for the companies’ supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) for… read more.
Lung cancer is the deadliest cancer in the United States, and 80% of lung cancer deaths are linked to one risk factor: smoking. While lung cancer screenings are… read more.
AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated (BRCAm) castration-resistant prostate cancer… read more.
The REIMAGINE study, published today in BMJ Oncology, is the first study to use MRI scans with prostate specific antigen (PSA) density to assess the need for further standard… read more.
Good cardiorespiratory fitness when young is associated with up to a 40% lower risk of developing 9 specific cancers later on—at least in men—suggests a large long term… read more.
A 67-year old patient presenting with oesophageal cancer was treated today at the Paul Scherrer Institute PSI with a form of radiation provided by protons, i.e. positively charged… read more.
Pfizer Inc. announced the FDA has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Akeega (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
